JP2022516662A5 - - Google Patents
Info
- Publication number
- JP2022516662A5 JP2022516662A5 JP2021539637A JP2021539637A JP2022516662A5 JP 2022516662 A5 JP2022516662 A5 JP 2022516662A5 JP 2021539637 A JP2021539637 A JP 2021539637A JP 2021539637 A JP2021539637 A JP 2021539637A JP 2022516662 A5 JP2022516662 A5 JP 2022516662A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789937P | 2019-01-08 | 2019-01-08 | |
| US62/789,937 | 2019-01-08 | ||
| PCT/US2020/012783 WO2020146529A1 (en) | 2019-01-08 | 2020-01-08 | Methods of treating conditions related to the s1p1 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516662A JP2022516662A (ja) | 2022-03-01 |
| JPWO2020146529A5 JPWO2020146529A5 (https=) | 2023-01-20 |
| JP2022516662A5 true JP2022516662A5 (https=) | 2023-01-20 |
Family
ID=69467760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539637A Ceased JP2022516662A (ja) | 2019-01-08 | 2020-01-08 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220142977A1 (https=) |
| EP (1) | EP3908276B1 (https=) |
| JP (1) | JP2022516662A (https=) |
| CN (2) | CN118976023A (https=) |
| AU (1) | AU2020206700A1 (https=) |
| CA (1) | CA3124701A1 (https=) |
| IL (1) | IL284114A (https=) |
| MX (1) | MX2021008263A (https=) |
| WO (1) | WO2020146529A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| US20210386706A1 (en) * | 2018-10-03 | 2021-12-16 | Arena Pharmaceuticals, Inc. | Methods for the treatment of scleroderma |
| US20220142977A1 (en) | 2019-01-08 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| WO2025177319A2 (en) * | 2024-02-22 | 2025-08-28 | Msn Laboratories Private Limited, R&D Center | Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA019252B1 (ru) | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| SI2342205T1 (sl) * | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| DK3311834T3 (da) * | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| MX386419B (es) * | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| JP6047203B2 (ja) * | 2015-02-20 | 2016-12-21 | セルセウティックス コーポレイション | 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬 |
| US20220142977A1 (en) | 2019-01-08 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
-
2020
- 2020-01-08 US US17/421,299 patent/US20220142977A1/en not_active Abandoned
- 2020-01-08 EP EP20703633.6A patent/EP3908276B1/en active Active
- 2020-01-08 WO PCT/US2020/012783 patent/WO2020146529A1/en not_active Ceased
- 2020-01-08 CA CA3124701A patent/CA3124701A1/en active Pending
- 2020-01-08 CN CN202411067321.3A patent/CN118976023A/zh active Pending
- 2020-01-08 JP JP2021539637A patent/JP2022516662A/ja not_active Ceased
- 2020-01-08 AU AU2020206700A patent/AU2020206700A1/en not_active Abandoned
- 2020-01-08 MX MX2021008263A patent/MX2021008263A/es unknown
- 2020-01-08 CN CN202080018255.4A patent/CN113874009A/zh active Pending
-
2021
- 2021-06-17 IL IL284114A patent/IL284114A/en unknown